Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 10Recurrence 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Oligodendroglioma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Breast Neoplasms 1Breast Carcinoma In Situ 1Brain Neoplasms 1Astrocytoma 1Adult Solid Neoplasm 1

Interventions

pembrolizumab 49Paclitaxel 20Carboplatin 19Cyclophosphamide 18Nivolumab 13Taxes 10130-nm albumin-bound paclitaxel 10olaparib 9Specimen Handling 9spartalizumab 8fludarabine 8Doxorubicin 8durvalumab 7Magnetic Resonance Spectroscopy 7Gemcitabine 7Biopsy 7veliparib 6atezolizumab 6Fulvestrant 6Cisplatin 6Albumin-Bound Paclitaxel 6liposomal doxorubicin 5eribulin 5budigalimab 5Irinotecan 5Ipilimumab 5aldesleukin 4Radiotherapy 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Triple Negative Breast Neoplasms × Introns × Clear all
NCT04081389 2023-09-11

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Roswell Park Cancer Institute

Phase 1 Completed
9 enrolled 17 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡